This search function provides links to outputs produced by NIHR Innovation Observatory. These are briefing notes or reports on new or repurposed technologies. This search will not return all technologies currently in development as these outputs are produced as required for our stakeholders.

Innovation Observatory > Reports > Drugs > Zilucoplan for treating generalised myasthenia gravis

< Back

Zilucoplan for treating generalised myasthenia gravis


Immunology and Allergy

September 2021

Zilucoplan is currently in clinical development for adult patients with class II-IV generalized Myasthenia Gravis (gMG) who are Acetylcholine Receptor (AChR) antibody positive. Myasthenia gravis (MG) is a rare and chronic autoimmune disease. MG results from an abnormal immune reaction in which the body’s natural immune defences (i.e., antibodies) inappropriately attack certain receptors in muscles, causing debilitating and potentially life-threatening muscle weakness. Currently there are no medicinal products recommended by NICE specifically for the treatment of gMG, and medicines that are used can take a long time to work and result in side-affects.
Zilucoplan is a synthetic peptide that works by attaching to and blocking the C5 complement protein, one of the proteins of the ‘complement system’, which is part of the body’s defence system. By blocking the C5 complement protein, zilucoplan is expected to prevent the complement system from damaging the blood cells, thereby helping to relieve the symptoms of the disease. Zilucoplan is administered via subcutaneous (SC) injection. If licenced, zilucoplan will provide a treatment option for those with gMG who are AChR antibody positive, reducing the treatment and disease burden in these patients.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Download Full Article


Connect to the Innovation Observatory


Load More Related Posts

Get Alerts